



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-IL-13 [CNTO607] Standard Size Ab03211-3.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Mouse IgG2b, Fc Silent™, Lambda

Clone Number: CNTO607

Alternative Name(s) of Target: IL13; NC30; Interleukin-13; MOR3406

UniProt Accession Number of Target Protein: P35225

Published Application(s): neutralize, ELISA

Published Species Reactivity: Human

Immunogen: The original antibody was generated from Morphosys HuCAL-Gold™ phage display library after panning against an IL-13 variant (R130Q) identified in a sub-population of patients who suffer from asthmatic attacks.

Specificity: This antibody binds an epitope at the surface formed by helices A and D of human interleukin-13. This epitope overlaps with the IL-4Ralpha/IL-13Ralpha1 receptor-binding site, which explains the neutralizing effect of CNTO607. IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, natural killer T cell, mast cells, basophils, eosinophils and nuocytes. It inhibits the production of inflammatory cytokines (IL-1, IL-6, TNF, IL-8) by LPS-stimulated monocytes. It synergizes with IL2 in regulating interferon-gamma synthesis. It is a mediator of allergic inflammation and different diseases including asthma.

Application Notes: The original IgG1 version of this antibody binds human IL-13 with an affinity of 18pM and prevents binding of IL-13 to both IL-13Rα1 and IL-4Rα. This antibody can bind native wild type and recombinant human IL-13 in an ELISA (PMID: 19361524). This antibody is capable of neutralizing IL13 activity in the TF-1 and in the IL-13Rα1 receptor binding assay (US20080044420). This antibody has the tendency to self associate. The IgG1 version of this antibody can be concentrated to ~13 mg/ml before irreversible precipitation occurs (PMID: 22915597). The relative binding affinity of the IgG1 version of this antibody was determined to be 18.4 pM (PMID: 22915597).

Antibody First Published in: Teplyakov et al. Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607. J Mol Biol. 2009 May 29;389(1):115-23. [PMID:19361524](#)

Note on publication: Describes the epitope mapping of this antibody using X-ray crystallography..

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.